ライフサイエンスコーパス: safety

1 enough or of long enough duration to draw conclusions about safety.

2 Limiting wasteful testing is important for patient safety.

3 ncluded overall survival (OS), objective response rate, and safety.

4 distribution is essential for evaluating their efficacy and safety.

5 e potentially injurious ingredients and thus promote public safety.

6 aintenance period were included in the primary efficacy and safety analyses.

7 re included as part of the assessment of mapping and in the safety analysis in an intention-to-treat manner.

8 ohort is closed, but patients are still being monitored for safety and anti-tumour activity.

9 Limited proof-of-concept monotherapy studies to evaluate safety and antiviral activity should be conducted prior to pr

10 Further studies are needed to better assess its safety and applicability.

11 Its safety and efficacy have been extensively demonstrated in cli

12 However, its safety and efficacy in preventing acute GVHD in settings of h

13 t clinical trial in which the first cohort assessed for the safety and efficacy of 12 weeks of sofosbuvir plus ribavirin

14 In this study, we investigated the safety and immunogenicity of an avian H5N2 live attenuated in

15 To evaluate the safety and intraocular pressure (IOP)-lowering effect of a bi

16 Further study is needed to assess safety and long-term clinical outcome.

17 ent of their gastrointestinal symptoms as well as treatment safety and tolerability.

18 In order are to achieve meaningful improvements in patient safety, and create harm free environments for patients, it is

19 yielded will lead to better patient care, enhanced patient safety, and ultimately facilitate a more predictable, optimal

20 is essential before the cells are introduced into chemical safety assessment.

21 The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans fo

22 udovirion vaccines may prove as efficacious and have better safety, but they have not been tested to date.

23 This highly sensitive p24 assay can help improve blood safety by reducing the antibody negative window period in blo

24 recommended early reporting of the study results because of safety concerns.

25 In this small study, no safety events were noted, but no safety conclusions can be drawn.

26 In this small study, no safety events were noted, but no safety conclusions can be dr

27 n patients with diabetic retinopathy, with no unanticipated safety events.

28 l feeding of spiked-blood meals, representing an additional safety feature.

29 umin are warranted to evaluate real-world effectiveness and safety in patients with type 1 hepatorenal syndrome.

30 thium/sodium metals, and hence eliminates the long-standing safety issue.

31 The data and safety monitoring board recommended early reporting of the st

32 atology can improve access to dermatologic care in a public safety-net hospital setting.

33 The efficacy and safety of 0.005% calcipotriol ointment combined with 5% 5-FU

34 To compare the efficacy and safety of 2 sclerosants used to treat reticular veins: 0.2% p

35 are contact for most children, we sought to investigate the safety of care provided to children in this setting.

36 We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial p

37 The primary objective of this trial was to evaluate safety of IVT or an estradiol vaginal ring in patients with e

38 Thermal treatment preserves the microbiological safety of milk, but also induces Maillard reactions modifying

39 We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patient

40 These findings challenge the safety of pure nicotine inhalation, i.e., E-cigarettes.

41 CLINICAL RELEVANCE: Relative safety of ranibizumab and bevacizumab is important in choosin

42 t studies strengthen the evidence base for the efficacy and safety of sublingual immunotherapy in patients with HDM-induc

43 levant RCTs and calculated pooled OR for 3-month mortality (safety outcome) and 3-month death or dependency (modified Ran

44 lop confidence communicating with others to improve patient safety, particularly in the areas of challenging poor practic

45 study findings underscore the importance of organizational safety practices and culture to promote safe work practices f

46 dard batch conditions, with short reaction times, increased safety profile, and potential to scale up.

47 esponse rate of 86% (95% CI, 83.0% to 88.7%), with no major safety signals.

48 o to receive 1200 million cells or placebo and assessed for safety through the first 7 days.

49 s overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one

50 Safety was generally similar between patients receiving immed